Yahoo Finance

Sanofi, Regeneron say latest Dupixent eczema drug tests positive

PARIS, March 4 (Reuters) - Drugmakers Sanofi and Regeneron said on Saturday results from a one-year test of their Dupixent product aimed at adults with eczema or moderate-to-severe atopic dermatitis ...
Yahoo Finance

Sanofi's Dupixent Gets FDA Approval for Eczema in Children

Sanofi SNY announced that the FDA has approved its blockbuster medicine Dupixent for treating children (aged between six and 11 years) with moderate-to-severe atopic dermatitis (AD) or eczema whose ...
The Spokesman-Review

People’s Pharmacy: Doctor endorses Dupixent for eczema

Q. In a recent article about the challenges of treating eczema (atopic dermatitis), you described a number of over-the-counter treatments as well as modern prescription medicines. In particular, you ...
Newswire

First targeted treatment for adults with moderate-to-severe atopic dermatitis, Dupixent™, now available in Canada

TORONTO, Feb. 8, 2018 /CNW/ - Dupixent™ (dupilumab) is now available in Canada for adult patients living with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with ...
Reuters

Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA

PARIS (Reuters) - The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron , the ...
Seeking Alpha

Sanofi and Regeneron's Dupixent gets approval in EU to treat eczema in kids over 6 months

The European Commission (EC) approved Sanofi (NASDAQ:SNY) and Regeneron Pharmaceuticals' (NASDAQ:REGN) Dupixent to treat severe atopic dermatitis (eczema) in children aged six months to five years old ...
Nasdaq

Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids

Sanofi SNY and partner Regeneron REGN announced that the European Commission has approved their blockbuster medicine, Dupixent, for children six months to five years of age with severe atopic ...
manilatimes

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

"Atopic dermatitis, a chronic disease with underlying type 2 inflammation, has a high prevalence and quality of life impact on patients with skin of color. Unique clinical features like darker patches ...
Yahoo

Danielle Jonas says her eczema affected her self-esteem and deterred her from going on tour often with Kevin Jonas and the Jonas Brothers

Danielle Jonas spoke to Insider about her experience with moderate eczema. Jonas said she was "uncomfortable with myself," before using Dupixent as a treatment for her condition. Because of her eczema ...

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...
JD Supra

First Dupixent Lawsuit Filed Over Fatal Lymphoma: What It Means for Patients and Families

The first known lawsuit has now been filed against the makers of Dupixent (dupilumab), alleging that the popular eczema and asthma drug caused or accelerated a deadly form of lymphoma. Filed in ...